Drug Profile
CLX 155
Alternative Names: Capacetabine/fluorouracil analogue; CLX-155; CLX-ONC-55; CLX-ONC-551Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Cellix Bio
- Class Antineoplastics; Carbamates; Pyrimidinones; Small molecules
- Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer
- Discontinued Gastric cancer; Head and neck cancer
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Breast-cancer in India (Parenteral)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Colorectal-cancer in India (Parenteral)
- 29 May 2020 Pharmacokinetics, pharmacodynamics and adverse events data from preclinical trials in Cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)